SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending as investors react to the company's recent leadership transition, the appointment of former Pfizer CMO Dr. Freda Lewis-Hall to its board, and anticipation surrounding upcoming Phase 2 data for its GAD program. The community remains polarized, with some highlighting the company's robust IP portfolio and institutional accumulation, while others express concerns over the stock's historical volatility and ongoing cash burn.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is facing downward pressure following significant insider selling by the CEO, sparking community frustration regarding management's long-term strategy and a desire for an acquisition. Despite these concerns, investors remain focused on the potential of the Casgevy commercial rollout and upcoming clinical data readouts across the firm's gene-editing pipeline.

Beamable Network is a decentralized compute infrastructure designed to power real games and digital experiences. Built by the team behind Beamable Inc.—a backend platform already serving over 95 live games—the network transforms compute into an open, tokenized marketplace. By combining distributed node operators, verifiable workloads, and blockchain incentives, Beamable Network provides scalable, cost-efficient infrastructure for any compute applications without dependence on centralized cloud providers.

Beamable Network Token

Beamable Network Token is experiencing heightened community interest driven by rapid price volatility and significant order book activity. Traders are actively tracking potential breakout patterns while debating the sustainability of the current momentum amid broader market speculation.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending as the community debates its future price trajectory and utility, with many holders actively discussing the potential for a significant token burn as a key catalyst. Conversations are heavily polarized, featuring both optimistic bulls predicting major rallies and skeptics dismissing the asset as part of a recurring meme coin cycle.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors weigh an upcoming Phase 3 readout for its hereditary angioedema therapy alongside significant volatility driven by high short interest and speculative sentiment. The community is actively debating the stock's potential as a binary event, with many focused on the interplay between clinical trial expectations, short-squeeze potential, and broader biotech sector momentum.

Chip

Chip is experiencing significant volatility and social media attention following its debut on major trading platforms, sparking a fierce debate among traders over whether it is a legitimate AI infrastructure utility or a speculative pump-and-dump scheme. The community is actively tracking support levels and debating the long-term potential of the token as it navigates price discovery and high trading volumes.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a significant management overhaul that includes the removal of CEO Peter Greenleaf and a total leadership restructuring led by the company's largest shareholder, Kevin Tang. The community is actively discussing the potential for an accelerated buyout and a strategic pivot to maximize shareholder value following these executive departures.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is facing intense scrutiny as a leadership transition to incoming CEO Josh D'Amaro highlights ongoing concerns regarding operational efficiency, content performance, and market stagnation. The community is actively debating the stock's long-term viability, weighing the company's streaming profitability and park demand against frustrations over persistent share price underperformance and polarizing creative strategies.

The Last Play is Crypto’s 401k.  RETIRE is more than a coin; it’s The Last Play. We are a community dedicated to breaking free from the grind and building true generational wealth. With RETIRE, our mission is simple yet profound: to provide a pathway to retire yourself and secure financial freedom for your bloodline. While others chase hype and trends, we’re focused on creating a legacy that lasts beyond the typical cycle. RETIRE is about making the one move that matters, with a vision for long-term value, freedom, and impact. This isn’t just a meme —it’s a purpose-driven commitment to building a legacy.

The Last Play

$RETIRE is capturing significant community attention as a grassroots movement aimed at replacing traditional 401(k) systems, with supporters actively participating in weekly dollar-cost averaging to fuel long-term growth. Investors are currently focused on its potential for a major breakout, viewing the token as a life-changing financial alternative that stands in defiance of established, centralized retirement models.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is trending as investors position for the upcoming May 31 PDUFA date for its ADHD candidate, CTx-1301, while closely monitoring for the imminent official grant of a U.S. patent. The community is actively debating the stock's volatility and the impact of potential manufacturing-related FDA inquiries versus the long-term potential of the firm's precision-timed release technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Galaxy said that ERCOT approval effectively doubles the data center’s capacity, taking it to over 1.6 gigawatts.</li><li>Construction is underway under the company’s long-term lease with CoreWeave, with initial power delivery expected in early 2026.</li><li>The company also announced the completion of its first-ever tokenized collateralized loan obligation, Galaxy CLO 2025-1, on the Avalanche blockchain platform. &nbsp;</li></ul>Galaxy Digital Inc. (GLXY) stock jumped 10% on Thursday as investors reacted to two major developments, including an approval for an additional 830 megawatts (MW) of power at its Helios data center campus in Texas, positioning the company for significant expansion in AI and high-performance computing infrastructure.The stock is on track to close in the green for a fourth successive session. <a href="https://stocktwits.com/symbol/GLXY">GLXY</a> was also among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">ERCOT Approval</h2>Galaxy said that the approval by the Electric Reliability Council of Texas (ERCOT) effectively doubles the data center’s previously approved power capacity, taking it to over 1.6 gigawatts (GW).Galaxy signed a service agreement with AEP Texas for the new capacity, with Wind Energy Transmission Texas (WETT) serving as the transmission interconnection provider.The company said that construction is underway under the company’s long-term lease with CoreWeave, with initial power delivery expected in early 2026. Galaxy added that it is exploring additional power and land opportunities in Texas and beyond.<h2 class="st-heading-2">Tokenized CLO Execution</h2>In a separate release, the company announced the completion of its first-ever tokenized collateralized loan obligation (CLO), Galaxy CLO 2025-1, on the Avalanche blockchain platform.The CLO supports a flexible credit line for Arch Lending, a crypto-backed consumer loan platform. It gradually buys loans backed by Bitcoin, Ethereum, and other crypto assets, and can grow up to $200 million as more loans are issued.“By uniting our strengths in debt capital markets, blockchain technology, and asset management, we're opening a new avenue for institutional engagement in credit markets—one that benefits from greater efficiency, transparency, and expanded collateral flexibility through onchain execution,” said Chris Ferraro, President and Chief Investment Officer at Galaxy.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits trended in the ‘extremely bullish’ territory at the time of writing, while message volumes were at ‘extremely high’ levels.<img src="https://news.stocktwits-cdn.com/GLXY_jpg_8447717cc7.webp" alt="GLXY.jpg">One user was bullish about the ERCOT approval, stating it gives Galaxy a major advantage in AI and HPC infrastructure.<stembedurl>https://stocktwits.com/KavaStocks/message/641919100</stembedurl>Another user saw the power expansion news as “massive” and expects the stock to climb to $50, a near 40% upside to the current price of $30.4.<stembedurl>https://stocktwits.com/justAuselessGhOsT/message/641900630</stembedurl>Over the past year, GLXY stock has gained over 60%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-sphl-stock-surge-over-270-oercent-today/cmU181cR4Jc">This Microcap Stock Surged Over 270% Today – What Triggered The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Galaxy Digital logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

GLXY Stock Rallied 10% Today – What Are The Two Factors At Play?

The company secured approval for an additional 830 megawatts of power at its Helios data center campus in Texas and completed its first-ever tokenized collateralized loan obligation.

Equity

The company secured approval for an additional 830 megawatts of power at its Helios data center campus in Texas and completed its first-ever tokenized collateralized loan obligation.


Market-Beating Crypto ETFs to Watch Before 2025 Ends

Crypto's explosive 2025 rally has pushed ETFs like BKCH and STCE sharply higher, putting them in focus for investors before the year ends. 

<ul class="summary-bullets"><li>VanEck now owns 2.2 million shares of Core Scientific and will vote against its merger with CoreWeave.</li><li>The investment management firm cited AI infrastructure potential as the primary reason for opposing the merger,</li><li>The firm added Core Scientific to its “laggards” list and sold its CoreWeave shares in the VanEck Onchain Economy ETF.</li></ul>Matthew Sigel, head of digital assets research at VanEck, said Thursday that the firm now owns 2.2 million shares of Core Scientific (CORZ) and will vote against the company’s planned merger with CoreWeave (CRWV).In morning trade,&nbsp;<a href="http://stocktwits.com/symbol/CORZ">Core Scientific’s stock</a> shares fell 2.7%, though retail sentiment on Stocktwits remained in ‘bullish’ territory, with chatter around the stock at ‘high’ levels over the past 24 hours.&nbsp;<a href="http://stocktwits.com/symbol/CRWV">CoreWeave’s stock</a> inched 0.6% higher, but retail sentiment shifted further into ‘bearish’ territory.<h2 class="st-heading-2">VanEck Cites AI Potential In Voting Against Merger</h2>According&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/matthew_sigel/status/1981364788190961850">to</a> Sigel, VanEck’s decision to oppose the deal between CoreWeave and Core Scientific stems from its belief in Core Scientific’s AI potential. With its stake, VanEck is now the 28th-largest shareholder in CORZ. The firm has also added Core Scientific to its “laggards” list, signaling a strategic focus on potential long-term upside rather than immediate merger outcomes.<blockquote>“We believe Core Scientific can help lead the next phase of AI infrastructure.”&nbsp;– Matthew Sigel, Head of Digital Assets Research, VanEck</blockquote>In a separate&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/matthew_sigel/status/1981368967894880754">post</a> on X, Sigel noted that VanEck sold the CoreWeave shares previously held in its VanEck Onchain Economy ETF (NODE).&nbsp;<a href="http://stocktwits.com/symbol/NODE">NODE</a> rose 1.3% in premarket trading, with retail sentiment around the ETF on Stocktwits largely in ‘neutral’ territory over the past day.<figure class="image"><a class="st-link-external" href="https://x.com/matthew_sigel/status/1981368967894880754" target="_blank" rel="noopener noreferrer nofollow"><img style="aspect-ratio:917/657;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_23_111605_png_9831e41748.webp" alt="Screenshot 2025-10-23 111605.png" width="917" height="657"></a><figcaption>Source: @matthew_sigel/X</figcaption></figure><h2 class="st-heading-2">Other Major Investors Also Voice Opposition</h2>In a CNBC&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/10/21/coreweave-ceo-on-core-scientific-deal-as-shareholder-opposition-rises.html">interview</a> earlier this week, CoreWeave CEO Michael Intrator described Core Scientific as a “nice to have” rather than a necessity, adding that the company would not increase its offer.However, VanEck is just the latest of investors to voice their chagrin. Proxy advisory firms ISS and Glass Lewis have also urged Core Scientific shareholders to vote against the merger, citing unfavorable terms. In a statement, Glass Lewis&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/second-leading-independent-proxy-advisory-firm-glass-lewis-joins-iss-in-recommending-core-scientific-shareholders-vote-against-proposed-sale-to-coreweave-on-gold-proxy-card-302590537.html">said</a>, “The market’s prolonged discount of the deal’s implied value to Core Scientific’s share price—combined with the absence of any mechanisms to mitigate downside risk—indicates that the proposed exchange does not adequately compensate Core Scientific shareholders for the risks inherent in the CoreWeave consideration.”CoreWeave&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.coreweave.com/news/news-details/2025/CoreWeave-Comments-on-Proxy-Advisor-Recommendations-Regarding-Proposed-Acquisition-of-Core-Scientific/default.aspx">responded</a> to ISS and Glass Lewis, stating that it disagreed with the advisory firms’ findings. “While neither ISS nor Glass Lewis questions the strategic merit of the transaction, both base their recommendations largely on the current Core Scientific stock price and overlook the risks of a standalone Core Scientific,” the company said.Two Seas Capital, one of Core Scientific’s largest shareholders, also opposes the transaction.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-on-track-to-hit-110-00-after-china-says-trade-talks-with-us-set-for-friday/cLG4W8vR3Ap">Bitcoin On Track To Hit $110,00 After China Says Trade Talks With US Set For Friday</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the logo of 'Core Scientific' is seen on a mobile phone screen in front of the 'CoreWeave' logos displayed on a computer in Ankara, Turkiye on July 17, 2025. (Photo by Mustafa Hatipoglu/Anadolu via Getty Images)

VanEck Opposes Core Scientific Merger With CoreWeave Citing AI Potential

The investment management firm cited AI infrastructure potential as the primary reason for opposing the merger,

NODE
VanEck Onchain Economy ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest NODE News

NODEVanEck Onchain Economy ETF